Polymeric nanoparticle platforms for ibrutinib delivery: tackling solubility, CYP3A4-mediated metabolism, and resistance to facilitate BTK-targeted therapy in solid tumours.
Because of its poor aqueous solubility, low oral bioavailability, extensive cytochrome P450 3A4 (CYP3A4)-mediated metabolism, and acquired resistance, ibrutinib, a first-in-class covalent Bruton's tyrosine kinase (BTK) inhibitor, has shown limited efficacy in solid tumors despite revolutionizing the treatment of B-cell...